Health Technology Assessment
Built by people who know what HTA will ask next
Health Technology Assessment
Our fully integrated HTA teams are experts in developing and critiquing evidence submissions for health technology agencies around the globe
At HEOR, we work closely with clients to make sure the full value of a therapy is clearly understood by the decision-makers who matter. We help shape evidence and arguments, so they work within the real-world environments in which reimbursement and access decisions are made
Demonstrating clinical effectiveness is essential for a therapy to reach patients, but it is rarely enough on its own. Payer and HTA decisions are also influenced by policy priorities, budget pressures, and evolving views of what represents good value for money
HTA bodies are not only asking whether a therapy works. They are asking whether it works for a clearly defined patient group, how it compares with existing options, whether its cost is justified, and how it fits within a specific healthcare system
Answering these questions convincingly requires a deep understanding of the decision-making context, and a value story that reflects the full impact of a therapy – including elements that may not sit neatly within standard assessment frameworks
We engage early, plan strategically, and build robust cases that support access to therapies for the patients who need them
Early-stage strategic planning
We get involved early, during evidence generation, to help ensure that the data being collected will be meaningful and persuasive for payers and HTA bodies
By anticipating evidentiary requirements and likely challenges during trial design, we reduce the risk of gaps or weaknesses becoming apparent only at submission
End-to-end submission support
We provide structured, rigorous support throughout the HTA process, from early scoping through to responding to clarification questions
Our focus is on ensuring that submissions are coherent, evidence-based, and tailored to the specific expectations and requirements of each assessment body
Value argumentation and framing
We work with clients to develop evidence strategies and value narratives that reflect the true clinical and economic impact of an asset
Standard assessment frameworks do not always capture where value genuinely lies – particularly when benefits extend beyond primary trial endpoints, affect the wider health system, enable access to other treatments, or emerge over longer time horizons than a clinical trial can reasonably observe
Navigating complex access decisions
We bring analytical rigour and independent strategic thinking to identifying the most credible and defensible path forward for assets where standard approaches have failed to capture the full picture
A restricted or negative recommendation does not necessarily represent a definitive assessment of a therapy’s value; it may reflect the limitations of the framework through which that value was evaluated
